|
|
 |
| hCMV-pp65 Antigen Delivery Reagent |
|
| Overview |
| The hCMV-pp65 Antigen Delivery Reagent has been developed for specific targeting of pp65 CMV antigen to antigen uptake receptors on human APCs. Such targeted delivery of antigen allows the analysis of antigen uptake, processing, and antigen presenting capability of targeted APCs. |
| Details |
Background information
The reagent consists of pp65 peptides covalently coupled to a dendrimer and a monoclonal, anti-biotin-FITC conjugate. Using a biotinylated primary antibody, the antigen can be specifically targeted to any surface molecule of the relevant APCs. This allows the identification and functional characterization of antigen uptake receptors, as well as research on vaccine strategies.1-3
Downstream applications
The hCMV-pp65 Antigen Delivery Reagent is well suited for analysis of
- antigen uptake by antigen-presenting cells, i.e., DCs, macrophages, and B cells.
- antigen processing and intracellular trafficking of endocytotic receptors.
- cross presentation of antigens. protocols for antigen delivery for DC vaccination.
|
| |
| Figure 1 |
| Plasmacytoid dendritic cells (PDCs) were isolated using BDCA-4 MicroBeads. PDCs were labeled with CD36-Biotin (A) or with a biotin-conjugated isotype control (B) followed by labeling with the hCMV-pp65 Antigen Delivery Reagent. Cells were cultured in the presence of CpG ODN for 24 hours that induces PDC maturation via toll-like receptor 9. Subsequently, PDCs were co-cultured with autologous memory effector CD4+ T cells at a ratio of 1:5 (PDC:T cell) for 20 hours by adding brefeldin A in the last 4 hours. Cells were fixed, permeabilized, and analyzed for intracellular IFN-γ by flow cytometry. |
| A |
 |
| B |
 |
|
|
|
|
| Favorites / Prices |
Request prices or add products to your favorite list.
|
| Details |
|
| Products |
| hCMV-pp65 Antigen Delivery Reagent |
| Storage/Shipping |
- 20 tests (1)
Download datasheet
130-095-406
|
| (1) One test corresponds to labeling of up to 106 cells in a total volume of 100 µL. |
|
| References |
| 1. Bonifaz, L. et al. (2002) J. Exp. Med. 196: 1627–1638. |
| 2. Dudziak, D. et al. (2007) Science 315: 107–111. |
| 3. Caminschi, I. et al. (2008) Blood 112: 3264–3273. |
|
|
|
© 1999 - 2012 Miltenyi Biotec ¦ Terms & conditions ¦ Legal notes
|
